Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Up 1,266.7% in January

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,100 shares, an increase of 1,266.7% from the January 15th total of 300 shares. Based on an average daily volume of 64,900 shares, the days-to-cover ratio is presently 0.1 days.

Defence Therapeutics Stock Performance

Shares of DTCFF remained flat at $0.80 during trading hours on Friday. The company had a trading volume of 4,000 shares, compared to its average volume of 34,267. The stock has a 50-day simple moving average of $0.50 and a two-hundred day simple moving average of $0.47. Defence Therapeutics has a twelve month low of $0.27 and a twelve month high of $1.45.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.